Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B)

• DOI: 10.1007/s12282-020-01192-y
• Publication Date: 2021-01-03T00:04:06Z
• Authors: Takamichi Yokoe; Sasagu Kurozumi; Kazuki Nozawa; Yukinori Ozaki; Tetsuyo Maeda; Shu Yazaki; Mai Onishi; Akihiro Fujimoto; Sayuka Nakayama; Yuko Tsuboguchi; Tsutomu Iwasa; Hitomi Sakai; Misato Ogata; Mitsuo Terada; Meiko Nishimura; Takuma Onoe; Jun Masuda; Michiko Kurikawa; Hirotsugu Isaka; Kanako Hagio; Akihiko Shimomura; Yuta Okumura; Manabu Futamura; Mototsugu Shimokawa; Toshimi Takano
• Keywords: Pertuzumab; Trastuzumab emtansine; Lapatinib; Taxane; Clinical endpoint

Abstract Background Trastuzumab emtansine (T-DM1) treatment for human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer after taxane with trastuzumab and pertuzumab is standard therapy. However, strategies beyond T-DM1 are still in development insufficient evidence of their effectiveness. Here, we aimed to evaluate real-world choice efficacy treatments HER2-positive cancer. Methods In this multi-centre retrospective cohort study involving 17 hospitals, 325 female patients whose post-T-DM1 began between April 15, 2014 December 31, 2018 were enrolled. The primary end point was the objective response rate (ORR) treatments. Secondary points included disease control (DCR), progression-free survival (PFS), time failure (TTF), overall (OS). Results median number prior four. types (1) chemotherapy combination ( n = 102; 31.4%), (2) concomitant 78; 24.0%), (3), lapatinib capecitabine 63; 19.4%), (4) others 82; 25.2%). ORR 22.8% [95% confidence interval (CI): 18.1–28.0], DCR 66.6% (95% CI 60.8–72.0), PFS 6.1 months 5.3–6.7), TTF 5.1 4.4–5.6), OS 23.7 20.7–27.4). Conclusion benefits limited. Further investigation new awaited patients.